Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | FABP1 | P07148 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 12/20 | 0.36 |
| ▸ | DRD3 | P35462 | 9/20 | 0.36 |
| ▸ | HTR1D | P28221 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 7/20 | 0.36 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 5/20 | 0.34 |
| ▸ | DRD5 | P21918 | 5/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064840 | 1.00 | PDE4A (0.37) | PDE4APDE4CPDE4DFABP1DRD2 | |
| SCHEMBL29889503 | 0.87 | PDE4A (0.39) | PDE4APDE4CPDE4DFABP1DRD2 | |
| SCHEMBL21315041 | 0.87 | PDE4A (0.39) | PDE4APDE4CPDE4DFABP1DRD2 | |
| SCHEMBL25184521 | 0.81 | PDE4A (0.41) | PDE4APDE4CPDE4DFABP1DRD2 | |
| SCHEMBL17080387 | 0.80 | FABP1 (0.40) | FABP1DRD2DRD3HTR1DDRD4 | |
| SCHEMBL25323447 | 0.80 | FABP1 (0.39) | PDE4APDE4CPDE4DFABP1DRD2 | |
| SCHEMBL12269000 | 0.79 | CYP2A6 (0.36) | PDE4APDE4CPDE4DFABP1CYP2A6 | |
| SCHEMBL22554976 | 0.79 | FABP1 (0.37) | PDE4APDE4CPDE4DFABP1DRD2 | |
| SCHEMBL30404831 | 0.79 | FABP1 (0.37) | PDE4APDE4CPDE4DFABP1DRD2 | |
| SCHEMBL19948204 | 0.78 | FABP1 (0.38) | PDE4APDE4CPDE4DFABP1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| EP-4216951-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022066646-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3908283-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| WO-2020146613-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | PDE4A 3222/4885PDE4C 2449/4885PDE4D 2771/4885 |
| US-20230357277-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | PDE4A 3446/4885PDE4C 3456/4885PDE4D 2207/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | PDE4A 3222/4885PDE4C 2449/4885PDE4D 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.